Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Antiviral Res. 2018 Jun 1;156:38–45. doi: 10.1016/j.antiviral.2018.05.013

Figure 4. Effect of galidesivir on A) survival outcome and B) percent weight change in hamsters challenged SC with RVFV (efficacy experiment 2).

Figure 4.

Animals in each group (n=10) were treated with the indicated loading and maintenance doses of galidesivir (mg/kg/day), ribavirin or placebo administered by IP injection for 7 days according to Table 3. The weight data are represented as the group mean and standard error of the mean of the percent change in weight of surviving animals relative to their starting weights on day 0. ***P < 0.001 compared to animals receiving placebo.